Boron Biologicals

Boron Biologicals, Inc. (BBI) was founded in 1986 by Dr. Bernard Spielvogel and is focused on the design, synthesis and commercial use of boronated compounds.

The company has strong research, development and commercial programs underway in three areas: human therapeutics, DNA diagnostics and biochemical research reagents.

HUMAN THERAPEUTICS

BBI is a leading supplier of compounds used for Boron Neutron Capture Therapy( BNCT ), a promising approach for the treatment of primary brain cancer and melanoma. BBI manufactures these compounds under FDA Drug Master File in a facility in North Carolina.

Boron Biologicals has also discovered and patented additional boronated compounds with specific therapeutic benefits. One group of compounds has demonstrated anti-osteoporotic activity in rodents by not only inhibiting bone resortion (loss), but also by stimulating bone formation. Other BBI molecules have shown strong anti-viral and anti-cancer properties in both cellular and animal models.

Additionally, BBI's patented boronated nucleosides offer strong promise in the emerging fields of antisense and gene therapy. In both of these technologies, the ability of a therapeutic molecule to cross a cell membrane, bond to DNA sequences, and accurately transcribe the genetic code is critical. BBI's nucleic acid technology appears to meet all of these requirements and further studies are underway to confirm these test results.

Boron Biologicals' strategy is to collaborate with existing biotechnology and pharmaceutical companies to further develop and commercialize these human therapeutics. BBI does not intend to conduct the full drug development process itself, but licenses its technology and provides research and manufacturing support to collaborative partners.

DNA DIAGNOSTICS

Boron Biologicals, Inc. has developed an extremely cost competitive PCR diagnostic technique, based on patented boronated nucleotides and a novel, patented detection method. Compared to leading alternative diagnostic techniques, the primary advantages of BBI's technology are: safety, speed, simplicity, low cost and greater quantifiability of results.

BBI is continuing the development of this novel PCR technique and has begun collaborative developmental efforts with a number of corporate partners.

BORONATED RESEARCH REAGENTS

Boron Biologicals has further leveraged its substantial expertise in boron chemistry to become a supplier of specialty boronated compounds used in research. BBI's catalog of over 100 boron-containing molecules provides researchers with the ability to use boron chemistry for development of novel biochemistries.